-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Glioblastoma is the most common primary malignant brain tumor with a poor prognosis.
Glioblastoma is the most common primary malignant brain tumor with a poor prognosis.
The currently established prognostic factors for glioblastoma include clinical factors such as age, surgical resection method, and genetic factors such as isocitrate dehydrogenase -1 (IDH1) mutation status and O-6 methylguanine-dna- Methyltransferase (MGMT) promoter methylation status.
In recent years, the risk stratification of radiomics before treatment in patients with glioblastoma has attracted more and more attention.
Recently, a study published in the journal European Radiology showed that the use of CNN-based subregional segmentation and the integration of survival predictions of various prognostic factors will help to effectively and early risk assessment of patients with glioblastoma.
In this single-center study, patients diagnosed with glioblastoma between October 2007 and December 2019 were retrospectively screened and grouped into training sets and tests at a ratio of 7:3 set.
In this single-center study, patients diagnosed with glioblastoma between October 2007 and December 2019 were retrospectively screened and grouped into training sets and tests at a ratio of 7:3 set.
A total of 120 patients were included in this study (85 in the training group, 35 in the test group).
Figure 1 (a) Overall survival rate (b) iAUC for progression-free survival.
Figure 1 (a) Overall survival rate (b) iAUC for progression-free survival.
Figure 2 (a) Overall survival rate (b) Multivariate Cox model prediction error curve for progression-free survival.
Figure 2 (a) Overall survival rate (b) Multivariate Cox model prediction error curve for progression-free survival.
This study proved the feasibility of using CNN- based multi-parameter segmentation and radiomic analysis of glioblastoma for clinical decision-making.
Original source: Original source:
Yangsean Choi,Yoonho Nam,Jinhee Jang,et al.
Yangsean Choi,Yoonho Nam,Jinhee Jang,et al.
Radiomics may increase the prognostic value for survival in glioblastoma patients when combined with conventional clinical and genetic prognostic models.
DOI: org/10.
1007/s00330-020-07335-1">10.
1007/s00330-020-07335-1 Yangsean Choi,Yoonho Nam, Jang Jinhee, et Al Radiomics on May Increase Survival the prognostic value for patients in glioblastoma When Combined with Conventional Clinical and prognostic Genetic Models the DOI:.
.
org/10.
1007/s00330-020-07335-1">10.
1007 / s00330-020-07335-1org/10.
1007/s00330-020-07335-1"> 10.
1007 / s00330-020-07335-1 in this message
